American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Matinas BioPharma Holdings, Inc.
$5.1MMarket cap
$1.1MRevenue · FY2023
-$10.3MNet income
2Employees
MTNBNYSE
2014IPO
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2023
- $1.1M
- Net income
- -$10.3M
- Total assets
- $7.2M
- Market cap
- $5.1M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 21, 2014
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Matinas BioPharma Holdings, Inc..
Write a review
Explore
Browse all →
